002653 海思科
已收盘 01-09 15:00:00
资讯
新帖
简况
1月7日海思科涨6.80%，中欧医疗健康混合A基金重仓该股
证券之星 · 01-07 15:38
1月7日海思科涨6.80%，中欧医疗健康混合A基金重仓该股
海思科(002653.SZ)：HSK39297片上市许可获受理
智通财经 · 01-06
海思科(002653.SZ)：HSK39297片上市许可获受理
海思科(002653.SZ)：“HSK50042”、“HSK55879”创新药IND申请获受理
智通财经 · 2025-12-30
海思科(002653.SZ)：“HSK50042”、“HSK55879”创新药IND申请获受理
海思科(002653.SZ)获得创新药HSK46575片新增适应症IND申请受理
智通财经 · 2025-12-22
海思科(002653.SZ)获得创新药HSK46575片新增适应症IND申请受理
海思科（002653）股东范秀莲质押236万股，占总股本0.21%
证券之星 · 2025-12-19
海思科（002653）股东范秀莲质押236万股，占总股本0.21%
海思科(002653.SZ)定增股票申请获深交所审核通过
智通财经 · 2025-12-18
海思科(002653.SZ)定增股票申请获深交所审核通过
海思科(002653.SZ)：多项药物临床试验获批准
智通财经 · 2025-12-16
海思科(002653.SZ)：多项药物临床试验获批准
海思科（002653）披露向特定对象发行股票审核问询函回复更新公告，12月15日股价下跌3.0%
证券之星 · 2025-12-15
海思科（002653）披露向特定对象发行股票审核问询函回复更新公告，12月15日股价下跌3.0%
海思科(002653.SZ)：安瑞克芬注射液被新增纳入国家医保目录
智通财经 · 2025-12-08
海思科(002653.SZ)：安瑞克芬注射液被新增纳入国家医保目录
海思科（002653）披露控股股东部分股份解除质押，12月1日股价下跌0.45%
证券之星 · 2025-12-01
海思科（002653）披露控股股东部分股份解除质押，12月1日股价下跌0.45%
海思科（002653）披露控股股东部分股份解除质押，11月24日股价上涨5.0%
证券之星 · 2025-11-24
海思科（002653）披露控股股东部分股份解除质押，11月24日股价上涨5.0%
11月24日海思科涨5.00%，中欧医疗健康混合A基金重仓该股
证券之星 · 2025-11-24
11月24日海思科涨5.00%，中欧医疗健康混合A基金重仓该股
海思科涨5.00%，东吴证券二个月前给出“买入”评级
证券之星 · 2025-11-24
海思科涨5.00%，东吴证券二个月前给出“买入”评级
海思科（002653）174万股限售股将于11月19日解禁，占总股本0.16%
证券之星 · 2025-11-19
海思科（002653）174万股限售股将于11月19日解禁，占总股本0.16%
11月16日海思科发布公告，股东减持912.34万股
证券之星 · 2025-11-16
11月16日海思科发布公告，股东减持912.34万股
海思科(002653.SZ)获得创新药HSK39297片新适应症《药物临床试验批准通知书》
智通财经 · 2025-11-13
海思科(002653.SZ)获得创新药HSK39297片新适应症《药物临床试验批准通知书》
海思科（002653）披露控股股东部分股份质押展期及解除质押，11月12日股价上涨2.05%
证券之星 · 2025-11-12
海思科（002653）披露控股股东部分股份质押展期及解除质押，11月12日股价上涨2.05%
海思科（002653）股东范秀莲质押222万股，占总股本0.2%
证券之星 · 2025-11-11
海思科（002653）股东范秀莲质押222万股，占总股本0.2%
海思科(002653.SZ)：HSK39297片新适应症药物临床试验获批准
智通财经 · 2025-11-03
海思科(002653.SZ)：HSK39297片新适应症药物临床试验获批准
股市必读：海思科10月31日涨停收盘，收盘价56.65元
证券之星 · 2025-11-03
股市必读：海思科10月31日涨停收盘，收盘价56.65元
加载更多
公司概况
公司名称：
海思科医药集团股份有限公司
所属行业：
医药制造业
上市日期：
2012-01-17
主营业务：
海思科医药集团股份有限公司的主营业务是新药研发、生产制造、推广营销业务。公司的主要产品是环泊酚注射液、苯磺酸克利加巴林胶囊、考格列汀片、安瑞克芬注射液。公司荣获2024年中国医药研发产品线“最佳工业企业”奖项。荣获“2024年度中国医药工业主营业务收入前100位企业”第88名。
发行价格：
20.00
{"stockData":{"symbol":"002653","market":"SZ","secType":"STK","nameCN":"海思科","latestPrice":56.18,"timestamp":1767942195000,"preClose":55,"halted":0,"volume":2700036,"delay":0,"changeRate":0.0215,"floatShares":483000000,"shares":1120000000,"eps":0.2759,"marketStatus":"已收盘","change":1.18,"latestTime":"01-09 15:00:00","open":55,"high":56.72,"low":54.55,"amount":151000000,"amplitude":0.0395,"askPrice":56.24,"askSize":13,"bidPrice":56.18,"bidSize":4,"shortable":0,"etf":0,"ttmEps":0.2759,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1768181400000},"marketStatusCode":5,"adr":0,"adjPreClose":55,"symbolType":"stock","openAndCloseTimeList":[[1767922200000,1767929400000],[1767934800000,1767942000000]],"highLimit":60.5,"lowLimit":49.5,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1119917970,"isCdr":false,"pbRate":14.57,"roa":"--","peRate":203.624502,"roe":"7.08%","epsLYR":0.35,"committee":-0.491749,"marketValue":62917000000,"turnoverRate":0.0056,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-01-12。","floatMarketCap":27148000000},"requestUrl":"/m/hq/s/002653","defaultTab":"news","newsList":[{"id":"2601782708","title":"1月7日海思科涨6.80%，中欧医疗健康混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2601782708","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601782708?lang=zh_cn&edition=full","pubTime":"2026-01-07 15:38","pubTimestamp":1767771497,"startTime":"0","endTime":"0","summary":"证券之星消息，1月7日海思科涨6.80%，收盘报56.35元，换手率1.42%，成交量6.84万手，成交额3.78亿元。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共41家，其中持有数量最多的公募基金为中欧基金的中欧医疗健康混合A。中欧医疗健康混合A目前规模为169.77亿元，最新净值1.8529，较上一交易日上涨0.45%，近一年上涨21.89%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010700018106.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","002653","BK0239","BK0033","BK0188","159760","BK0077"],"gpt_icon":0},{"id":"2601862140","title":"海思科(002653.SZ)：HSK39297片上市许可获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2601862140","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601862140?lang=zh_cn&edition=full","pubTime":"2026-01-06 16:04","pubTimestamp":1767686694,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海思科(002653.SZ)公告，公司子公司四川海思科制药有限公司于2026年1月6日收到国家药品监督管理局下发的《受理通知书》，相关药品名称为：HSK39297片，申请适应症为：适用于治疗既往未接受过补体抑制剂治疗的阵发性睡眠性血红蛋白尿症(PNH)成人患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1389263.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"海思科(002653.SZ)：HSK39297片上市许可获受理","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","002653","BK0028","BK0239","BK0033","BK0077"],"gpt_icon":0},{"id":"2595670427","title":"海思科(002653.SZ)：“HSK50042”、“HSK55879”创新药IND申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2595670427","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595670427?lang=zh_cn&edition=full","pubTime":"2025-12-30 16:20","pubTimestamp":1767082829,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海思科 发布公告，公司子公司上海海思盛诺医药科技有限公司于近日收到国家药品监督管理局下发的《受理通知书》，涉及产品：“HSK50042”、“HSK55879”。本次申请为HSK50042片在呼吸系统疾病领域中又一新适应症的临床试验申请，有望为呼吸疾病患者提供一种高效、安全的新型治疗选择。HSK55879片是公司自主研发的具有独立知识产权的口服小分子激动剂药物，拟用于代谢系统疾病的治疗。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1387080.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0033","BK0239","06978","002653","BK0188","BK1574","BK0077","BK0028","IND","BK1161","159992"],"gpt_icon":0},{"id":"2593485369","title":"海思科(002653.SZ)获得创新药HSK46575片新增适应症IND申请受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2593485369","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593485369?lang=zh_cn&edition=full","pubTime":"2025-12-22 17:36","pubTimestamp":1766396197,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海思科 发布公告，公司子公司辽宁海思科制药有限公司于近日收到国家药品监督管理局下发的《受理通书》，涉及药品：“HSK46575”。本次获得受理的为本品联合奥拉帕利片或联合多西他赛和泼尼松片用于前列腺癌的治疗适应症的临床试验申请。HSK46575片是公司自主研发的一种口服、强效和高选择性的小分子抑制剂，拟用于前列腺癌的治疗。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384452.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002653","BK0188","BK1161","IND","BK1574","BK0033","BK0239","BK0077","06978","BK0028","159992"],"gpt_icon":0},{"id":"2592415183","title":"海思科（002653）股东范秀莲质押236万股，占总股本0.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592415183","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592415183?lang=zh_cn&edition=full","pubTime":"2025-12-19 00:24","pubTimestamp":1766075078,"startTime":"0","endTime":"0","summary":"证券之星消息，海思科12月19日公开信息显示，股东范秀莲向国泰海通证券股份有限公司合计质押236.0万股，占总股本0.21%。质押详情见下表：截止本公告日，股东王俊民已累计质押股份5344.0万股，占其持股总数的13.38%，股东范秀莲已累计质押股份5559.0万股，占其持股总数的25.58%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121900000239.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","002653","BK0033","BK0028","BK0077","BK0239"],"gpt_icon":0},{"id":"2592032339","title":"海思科(002653.SZ)定增股票申请获深交所审核通过","url":"https://stock-news.laohu8.com/highlight/detail?id=2592032339","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592032339?lang=zh_cn&edition=full","pubTime":"2025-12-18 20:24","pubTimestamp":1766060647,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海思科(002653.SZ)公告，公司于2025年12月18日收到深圳证券交易所上市审核中心出具的《关于海思科医药集团股份有限公司申请向特定对象发行股票的审核中心意见告知函》。深交所上市审核中心对公司提交的向特定对象发行股票的申请文件进行了审核，认为公司符合发行条件、上市条件和信息披露要求，后续深交所将按规定报中国证券监督管理委员会履行相关注册程序。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1383321.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"海思科(002653.SZ)定增股票申请获深交所审核通过","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0033","BK0188","BK0239","BK0077","BK0028","002653"],"gpt_icon":0},{"id":"2591604664","title":"海思科(002653.SZ)：多项药物临床试验获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2591604664","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591604664?lang=zh_cn&edition=full","pubTime":"2025-12-16 16:11","pubTimestamp":1765872669,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海思科(002653.SZ)公告，公司子公司上海海思盛诺医药科技有限公司于近日收到国家药品监督管理局下发的《药物临床试验批准通知书》，HSK45019片、HSK50042片、注射用HSK55718、HSK36357胶囊获准开展临床试验，相对应适应症分别为：炎症性肠病、呼吸系统疾病、急性疼痛、肌营养不良症。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1382056.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"海思科(002653.SZ)：多项药物临床试验获批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002653","BK0188","BK0028","BK0239","BK0077","BK0033"],"gpt_icon":0},{"id":"2591475306","title":"海思科（002653）披露向特定对象发行股票审核问询函回复更新公告，12月15日股价下跌3.0%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591475306","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591475306?lang=zh_cn&edition=full","pubTime":"2025-12-15 22:41","pubTimestamp":1765809668,"startTime":"0","endTime":"0","summary":"截至2025年12月15日收盘，海思科报收于53.06元，较前一交易日下跌3.0%，最新总市值为594.23亿元。公司近日发布公告称，其已于2025年7月23日收到深圳证券交易所出具的关于公司申请向特定对象发行股票的审核问询函。本次向特定对象发行股票事项尚需通过深交所审核，并获得中国证监会同意注册，最终能否实施及审批时间存在不确定性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121500036467.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0028","BK0077","BK0239","BK0033","002653"],"gpt_icon":0},{"id":"2589325385","title":"海思科(002653.SZ)：安瑞克芬注射液被新增纳入国家医保目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2589325385","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589325385?lang=zh_cn&edition=full","pubTime":"2025-12-08 11:48","pubTimestamp":1765165721,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海思科 发布公告，国家医保局、人力资源社会保障部于2025年12月7日发布了《关于印发<国家基本医疗保险、生育保险和工伤保险药品目录>以及<商业健康保险创新药品目录>>的通知》。公司的环泊酚注射液成功续约，安瑞克芬注射液被新增纳入《国家医保目录》。公司目前共有包括环泊酚注射液、安瑞克芬注射液、苯磺酸克利加巴林胶囊、考格列汀片在内的四个1类创新药被纳入国家医保目录。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378671.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002653","BK0188","BK0028","BK0077","BK0033","BK0239"],"gpt_icon":0},{"id":"2588776140","title":"海思科（002653）披露控股股东部分股份解除质押，12月1日股价下跌0.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588776140","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588776140?lang=zh_cn&edition=full","pubTime":"2025-12-01 22:55","pubTimestamp":1764600903,"startTime":"0","endTime":"0","summary":"截至2025年12月1日收盘，海思科报收于59.55元，较前一交易日下跌0.45%，最新总市值为666.91亿元。公司近日发布公告，控股股东王俊民先生近期解除部分股份质押。本次合计解除质押股份1,000万股，占其持有股份的2.50%，占公司总股本的0.89%。其中480万股因到期解除质押，质权人为平安证券股份有限公司；520万股经协商提前解除质押，质权人为国泰海通证券股份有限公司。截至公告日，王俊民累计质押股份5,344万股，占其所持股份的13.38%，占公司总股本的4.77%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120100037950.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","BK0077","BK0188","BK0033","002653"],"gpt_icon":0},{"id":"2585498752","title":"海思科（002653）披露控股股东部分股份解除质押，11月24日股价上涨5.0%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585498752","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585498752?lang=zh_cn&edition=full","pubTime":"2025-11-24 22:42","pubTimestamp":1763995347,"startTime":"0","endTime":"0","summary":"近日，海思科医药集团股份有限公司发布公告，公司控股股东及实际控制人王俊民先生所持有的750万股公司股份已于2025年11月21日解除质押，占其所持股份比例的1.88%，占公司总股本的0.67%。本次质押起始日为2023年11月22日，质权人为平安证券股份有限公司，解除原因为到期解除质押。截至公告披露日，王俊民累计质押股份6,344万股，占其所持股份的15.88%，占公司总股本的5.66%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112400036455.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0033","BK0188","BK0239","BK0077","BK0028","002653"],"gpt_icon":0},{"id":"2585705459","title":"11月24日海思科涨5.00%，中欧医疗健康混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2585705459","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585705459?lang=zh_cn&edition=full","pubTime":"2025-11-24 15:39","pubTimestamp":1763969999,"startTime":"0","endTime":"0","summary":"证券之星消息，11月24日海思科涨5.00%，收盘报59.0元，换手率1.13%，成交量5.46万手，成交额3.13亿元。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共41家，其中持有数量最多的公募基金为中欧基金的中欧医疗健康混合A。中欧医疗健康混合A目前规模为169.77亿元，最新净值1.827，较上一交易日下跌1.92%，近一年上涨9.39%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112400013316.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","002653","159760","BK0077","BK0033","BK0028"],"gpt_icon":0},{"id":"2585745906","title":"海思科涨5.00%，东吴证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2585745906","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585745906?lang=zh_cn&edition=full","pubTime":"2025-11-24 15:39","pubTimestamp":1763969990,"startTime":"0","endTime":"0","summary":"今日海思科（002653）涨5.00%，收盘报59.0元。2025年8月28日，东吴证券研究员朱国广,张翀翯发布了对海思科的研报《2025年中报点评：麻醉产品销售符合预期，创新管线进入商业化兑现期》，该研报对海思科给出“买入”评级。证券之星数据中心根据近三年发布的研报数据计算，该研报作者对此股的盈利预测准确度为69.72%。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为华泰证券的李奕玮、唐庆雷、代雯。海思科（002653）个股概况：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112400013314.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601555","002653"],"gpt_icon":0},{"id":"2584275962","title":"海思科（002653）174万股限售股将于11月19日解禁，占总股本0.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584275962","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584275962?lang=zh_cn&edition=full","pubTime":"2025-11-19 08:05","pubTimestamp":1763510712,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，海思科于11月19日将有174.0万股限售股份解禁，为公司股权激励限售股份，占公司总股本0.16%。最近一年内，该股累计解禁108.0万股，占总股本的0.1%。本次解禁后，公司还有6.37亿股限售股份，占总股本56.85%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111900004949.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0077","BK0033","BK0028","BK0239","002653"],"gpt_icon":0},{"id":"2583669779","title":"11月16日海思科发布公告，股东减持912.34万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2583669779","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583669779?lang=zh_cn&edition=full","pubTime":"2025-11-16 18:01","pubTimestamp":1763287290,"startTime":"0","endTime":"0","summary":"证券之星消息，11月16日海思科发布公告《海思科:关于控股股东一致行动人减持计划实施完成的公告》，其股东申萍于2025年9月13日至2025年11月14日间合计减持912.34万股，占公司目前总股本的0.8146%，变动期间该股股价下跌3.82%，截止11月14日收盘报55.86元。股东增减持详情见下表：根据海思科2025年三季报公布的十大股东详情如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111600008716.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","002653","BK0033","BK0188","BK0077","BK0239"],"gpt_icon":0},{"id":"2583559792","title":"海思科(002653.SZ)获得创新药HSK39297片新适应症《药物临床试验批准通知书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2583559792","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583559792?lang=zh_cn&edition=full","pubTime":"2025-11-13 15:45","pubTimestamp":1763019913,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海思科(002653.SZ)发布公告，公司近日收到国家药品监督管理局下发的《药物临床试验批准通知书》，经审查，2025年8月受理的HSK39297片临床试验申请符合药品注册的有关要求，同意开展临床试验。HSK39297片是公司自主研发的一个全新的具有独立知识产权的治疗年龄相关性黄斑变性的药物。临床前研究结果表明，本品靶点明确、疗效确切、安全性好，是一款极具开发潜力的小分子药物，临床应用的效益/风险比高，具有广阔的临床应用前景，有望成为AMD的有效治疗药物，解决目前临床用药匮乏的难题。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1368748.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","159992","BK0188","002653","BK0028","BK0239","BK1161","BK0033","BK0077","06978"],"gpt_icon":0},{"id":"2582377248","title":"海思科（002653）披露控股股东部分股份质押展期及解除质押，11月12日股价上涨2.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582377248","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582377248?lang=zh_cn&edition=full","pubTime":"2025-11-12 22:34","pubTimestamp":1762958057,"startTime":"0","endTime":"0","summary":"公司近日发布公告称，控股股东王俊民先生对其持有的公司部分股份进行了质押展期及解除质押操作。本次质押展期数量为234万股，占其所持股份比例0.59%，占公司总股本比例0.21%，展期后到期日为2026年11月11日或质权人办理完毕解除质押登记手续之日，质权人为中信证券股份有限公司，质押用途为自身生产经营。截至公告披露日，王俊民累计质押股份数量为7,094万股，占其所持股份比例17.75%，占公司总股本比例6.33%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111200041500.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002653","BK0188","BK0028","BK0239","BK0077","BK0033"],"gpt_icon":0},{"id":"2582935063","title":"海思科（002653）股东范秀莲质押222万股，占总股本0.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582935063","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582935063?lang=zh_cn&edition=full","pubTime":"2025-11-11 18:28","pubTimestamp":1762856925,"startTime":"0","endTime":"0","summary":"证券之星消息，海思科11月11日公开信息显示，股东范秀莲向国金证券资产管理有限公司合计质押222.0万股，占总股本0.2%。质押详情见下表：截止本公告日，股东王俊民已累计质押股份7397.0万股，占其持股总数的18.51%，股东范秀莲已累计质押股份5323.0万股，占其持股总数的24.49%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111100032470.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0033","BK0239","002653","BK0188","BK0028"],"gpt_icon":0},{"id":"2580440264","title":"海思科(002653.SZ)：HSK39297片新适应症药物临床试验获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2580440264","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580440264?lang=zh_cn&edition=full","pubTime":"2025-11-03 16:16","pubTimestamp":1762157761,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海思科(002653.SZ)公告，公司近日收到国家药品监督管理局审评中心下发的《药物临床试验批准通知书》，药品名称为HSK39297片，其适应症为全身型重症肌无力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1364433.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK0239","BK0033","BK0188","BK0077","002653"],"gpt_icon":0},{"id":"2580280895","title":"股市必读：海思科10月31日涨停收盘，收盘价56.65元","url":"https://stock-news.laohu8.com/highlight/detail?id=2580280895","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580280895?lang=zh_cn&edition=full","pubTime":"2025-11-03 01:11","pubTimestamp":1762103469,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘，海思科报收于56.65元，上涨10.0%，涨停，换手率2.16%，成交量10.38万手，成交额5.7亿元。来自交易信息汇总：10月31日主力资金净流入9277.82万元，散户资金净流出9591.57万元。交易信息汇总海思科10月31日涨停收盘，收盘价56.65元。该股于14点16分涨停，未打开涨停，截止收盘封单资金为1130.59万元，占其流通市值0.04%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110300000274.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0028","BK0077","BK0239","BK0033","002653"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1768006494544,"stockEarnings":[{"period":"1week","weight":0.0947},{"period":"1month","weight":-0.0393},{"period":"3month","weight":0.0885},{"period":"6month","weight":0.2667},{"period":"1year","weight":0.8474},{"period":"ytd","weight":0.0947}],"compareEarnings":[{"period":"1week","weight":0.0382},{"period":"1month","weight":0.0564},{"period":"3month","weight":0.0573},{"period":"6month","weight":0.1739},{"period":"1year","weight":0.2831},{"period":"ytd","weight":0.0382}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"海思科医药集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"12894人(较上一季度增加12.87%)","perCapita":"37477股","listingDate":"2012-01-17","address":"西藏自治区山南市乃东区泽当镇三湘大道17号","registeredCapital":"111991万元","survey":" 海思科医药集团股份有限公司的主营业务是新药研发、生产制造、推广营销业务。公司的主要产品是环泊酚注射液、苯磺酸克利加巴林胶囊、考格列汀片、安瑞克芬注射液。公司荣获2024年中国医药研发产品线“最佳工业企业”奖项。荣获“2024年度中国医药工业主营业务收入前100位企业”第88名。","listedPrice":20},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"海思科(002653)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供海思科(002653)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"海思科,002653,海思科股票,海思科股票老虎,海思科股票老虎国际,海思科行情,海思科股票行情,海思科股价,海思科股市,海思科股票价格,海思科股票交易,海思科股票购买,海思科股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"海思科(002653)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供海思科(002653)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}